The Economic Value of Tildrakizumab Treatment in Patients With Moderate-to-Severe Plaque Psoriasis: A Norwegian Perspective


Por: Tveit, KS, Costanzo, A, Du Jardin, KG, Sarno, A and Carrascosa, JM

Publicada: 1 ene 2025
Resumen:
Chronic plaque psoriasis negatively impacts patients' work productivity, with potential substantial financial implications. This post hoc analysis assessed associations between disease (itch, pain, dermatology life quality index [DLQI], and psoriasis area and severity index [PASI])- and work-related outcome measures (absenteeism, presenteeism, and activity and work impairment) in 116 patients with moderate-to-severe plaque psoriasis treated with tildrakizumab for 24 weeks. We extrapolated the potential economic value of reducing work productivity loss with tildrakizumab treatment in society, using Norway as a model. Elevated pain and DLQI scores significantly increased the degree of absenteeism, and pain, DLQI, and itch were significantly positively associated with presenteeism, activity impairment, and work impairment. The PASI did not associate with any work outcome measure. Economic impact due to work productivity loss was extrapolated at approximately EUR 12,700 per person annually. In conclusion, all disease outcome measures except the PASI were associated with a work-related outcome measure, indicating that more holistic measures for assessing psoriasis disease burden may be more beneficial from a patient perspective. Additionally, the economic value of reduced work productivity loss due to tildrakizumab treatment was extrapolated to be substantial in Norwegian society, suggesting that managing plaque psoriasis with this biologic could be clinically and economically beneficial.

Filiaciones:
Tveit, KS:
 Haukeland Hosp, Dept Dermatol, Haukelandsveien 22, N-5021 Bergen, Norway

Costanzo, A:
 Humanitas Univ, Dept Biomed Sci, Sect Dermatol, Via Rita Levi Montalcini 4 Pieve Emanuele, I-20090 Milan, Italy

 IRCCS Humanitas Res Hosp, Dermatol Unit, Via Manzoni 56 Rozzano, I-20089 Milan, Italy

Du Jardin, KG:
 Almirall R&D, Ronda Gen Mitre 151, Barcelona 08022, Spain

Sarno, A:
 Almirall R&D, Ronda Gen Mitre 151, Barcelona 08022, Spain

:
 Hosp Univ Germans Trias i Pujol, Dept Dermatol, Carretera Canyet S-N, Badalona 08916, Spain
ISSN: 15298019





Dermatologic Therapy
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 2025 Número: 1
Páginas:
WOS Id: 001648290800001
imagen gold

MÉTRICAS